Sgx Pharmaceuticals, Inc.

Irm LLC

Novartis Ag

Ruo W Steensma

Mark E Wilson

William D Arnold

Andreas Gosberg

Ian A McDonald

Zhe Li

Stephanie Hopkins

Stefan N Gradl

Chixu Chen

Pierre Bounaud

Nathanael Schiander Gray

Brian Walter Eastman

Paul A Sprengeler

Yi Liu

Jiqing Jiang

Greg Chopiuk

Gavin C Hirst

Qiang Ding

Pierre-Yves Bounaud

Masaki Tomimoto

Zhe Li Bounaud

Pascal Furet

Donald Karanewsky

Qiong Zhang

Yongqin Wan

Xing Wang

Johnny Uy

Yongping Xie

Keiichi Masuya

Ichiro Umemura

Joseph Schoepfer

Taebo Sim

Carlos Garcia-Echeverria

Shuli You

Patricia Imbach

Takanori Kanazawa

Naoko Matsuura

Osamu Ohmori

Takahiro Miyake

Eiji Kawahara

Richard Pracitto

Khanh Thi Tuong Nguyen

Jeffrey M Blaney

Paul E Sprengeler

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

Fused ring heterocycle kinase modulators

The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.

Pyrimidinyl-thiophene kinase modulators

The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

Pyrrolo-pyridine kinase modulators

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2&#x3b1;, p38, TGF&#x3b2;, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.

Compounds and compositions as protein kinase inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2&#x3b2; kinases.

Growing community of inventors

La Jolla, CA, United States of America

Ruo W Steensma